XXXX Does Not Predict for @entity263 Diagnosis, Grade, or Volume of Disease After Transperineal Template-guided Mapping Biopsy.

@entity1 @entity263 @entity6 @entity5 @entity5436 @entity1486 @entity2449
OBJECTIVES:: Previous studies have evaluated whether @entity2449 is associated with @entity263 incidence and outcomes with conflicting conclusions. In this study, we evaluate the incidence of @entity263 in @entity6 @entity1 treated with and without @entity2449 compared with nondiabetic @entity1 . MATERIALS AND METHODS:: One thousand thirty-four @entity1 underwent transperineal template-guided mapping biopsy secondary to either an elevated @entity1486 or a prior biopsy finding of atypical small acinar proliferation/ @entity5436 . The cohort included 881 nondiabetic @entity1 , 65 @entity6 @entity1 treated with @entity2449 , and 88 @entity6 @entity1 not receiving @entity2449 . In @entity2449 -treated @entity1 , the median duration of usage was 6.0 years. Differences in @entity263 diagnosis, histologic grade, and @entity5 volume were compared across the 3 cohorts. RESULTS:: There was no statistically significant differences discerned between the 3 cohorts in @entity1 age, prebiopsy @entity1486 , prostate volume, @entity1486 density, @entity1486 doubling time, @entity1486 velocity, or the total number of prior transrectal ultrasound biopsy sessions. Five hundred eighty-four @entity1 were diagnosed with @entity263 . There was no difference in @entity263 diagnosis (P=0.153), Gleason score (P=0.960), the number of positive biopsy cores (P=0.764), or risk group stratification (P=0.877) between the 3 cohorts. In multivariate analysis, only older age predicted for @entity263 diagnosis. In terms of Gleason score >= 7, @entity1 age, @entity1486 velocity, and body mass index predicted for more aggressive histology. Neither @entity6 , @entity2449 use or duration was of statistical consequence. CONCLUSION:: @entity2449 did not impact incidence of @entity263 diagnosis, Gleason score distribution, or volume of disease.
